Care for memory and thinking

What a cognitive neurologist does, from the first evaluation to long-term support, explained step by step.

Written by Dr. Neelum Aggarwal, MD, cognitive neurologist Last reviewed Sources cited Editorial policy

Memory evaluation

A careful look at what has changed, why, and what it means for daily life.

  • A detailed history with you and, ideally, someone who knows you well
  • Standardized tests of memory, attention, language and problem-solving
  • Neurological and general physical examination
  • Blood tests for treatable contributors such as low vitamin B12 or thyroid problems
  • Brain imaging, usually MRI, when it helps answer the question
  • Referral for in-depth neuropsychological testing when needed

Diagnosis & ongoing care

A clear explanation of the findings and a plan that changes as needs change.

  • Explaining the diagnosis: MCI, Alzheimer's disease, vascular cognitive impairment or another cause
  • Biomarker testing (PET, spinal fluid or blood) when it would change decisions
  • Reviewing medicines that may worsen thinking
  • Discussing symptomatic medicines and, where appropriate, anti-amyloid therapy
  • Follow-up to track changes over time
  • Safety topics such as driving, finances and living alone

Heart & brain health

Cognitive care that takes heart and blood-vessel health seriously.

  • Cognitive concerns in people with heart disease, atrial fibrillation or stroke risk
  • Vascular cognitive impairment
  • Risk-factor review: blood pressure, blood sugar, cholesterol, sleep
  • Coordination with cardiology through the Rush Cardiology Cognitive Clinic
  • Attention to women's specific risks across midlife and later life

Brain health & risk

Practical, evidence-based steps for people who want to protect their thinking.

  • Review of the 14 modifiable risk factors identified by the 2024 Lancet Commission
  • Hearing, vision, sleep and mood checks
  • Physical activity and diet guidance grounded in current trials
  • Honest advice about supplements and online 'brain' products

Support for families

Care partners are part of the team, and they need support too.

  • Including care partners in visits and decisions
  • Planning ahead: legal, financial and care decisions
  • Help with changes in mood, sleep and behavior
  • Connecting families with community resources, such as the Alzheimer's Association 24/7 Helpline
  • Recognizing and addressing caregiver strain

Research consultation

Help deciding whether research participation makes sense for you.

  • Explaining how clinical trials and observational studies work
  • What informed consent means and what to ask
  • Where to look: ClinicalTrials.gov and TrialMatch
  • How research fits alongside regular care

Services are provided through Rush University Medical Center clinics, and what's available can vary. Please confirm details when the office replies to you.

Q.

What actually happens at each step?

Who each test or treatment is for, what it involves, and what to know beforehand.

Cognitive evaluation visit

Who it's for
Anyone with new or worsening problems with memory, thinking, language or judgment, or whose family has noticed changes.
What happens
A long conversation about what has changed, medical history, medicines, mood and sleep; brief thinking tests; and a neurological exam.
How to prepare
Bring a medicine list and, if possible, a family member. Plan for a longer visit than usual.
Good to know
The first visit often ends with a plan for tests rather than a final answer.

Neuropsychological testing

Who it's for
People whose results are borderline, unusual, or need a detailed baseline.
What happens
Several hours of pencil-and-paper and computer tasks with a neuropsychologist, measuring different thinking skills against people of similar age and education.
How to prepare
Rest well beforehand and wear glasses and hearing aids. Breaks are allowed.
Good to know
Results describe strengths as well as weaknesses, which helps with practical planning.

Brain MRI

Who it's for
Most people having a memory evaluation, and everyone considering anti-amyloid therapy.
What happens
A scan that shows strokes, small-vessel disease, shrinkage patterns, tumors or bleeding that could explain symptoms.
How to prepare
Tell the team about pacemakers, implants or claustrophobia.
Good to know
MRI is also used to monitor safety during anti-amyloid treatment.

Alzheimer's biomarker tests

Who it's for
People with cognitive symptoms when knowing whether Alzheimer's changes are present would change decisions.
What happens
An amyloid PET scan, a spinal-fluid test or, increasingly, a validated blood test, used within a full evaluation.
How to prepare
Ask what the result could mean before you take the test, and how it will be shared.
Good to know
Blood tests are not intended for people without symptoms.

APOE genetic testing

Who it's for
People considering anti-amyloid therapy, where it is recommended before treatment.
What happens
A blood or saliva test for the APOE gene, which affects Alzheimer's risk and the risk of treatment side effects.
How to prepare
Results can have implications for relatives; counseling beforehand is important.
Good to know
Carrying APOE ε4 raises risk but does not mean someone will develop Alzheimer's.

Anti-amyloid therapy pathway

Who it's for
Selected people with MCI or mild dementia due to Alzheimer's disease, with amyloid confirmed.
What happens
Eligibility checks, shared decision-making, then IV infusions (lecanemab or donanemab) or subcutaneous injections (lecanemab), with scheduled MRI monitoring.
How to prepare
Treatment involves regular visits and scans over many months.
Good to know
Not everyone is a candidate; choosing not to start is also a reasonable decision.

Symptomatic medicines

Who it's for
People with Alzheimer's dementia and some other dementias.
What happens
Medicines such as cholinesterase inhibitors or memantine, which may help memory and daily function for a time without changing the underlying disease.
How to prepare
Side effects such as nausea, vivid dreams or dizziness are reviewed at follow-up.
Good to know
Benefits vary; the plan is reviewed regularly.

Care planning visit

Who it's for
People living with a diagnosis and their care partners.
What happens
Time to talk through safety, driving, finances, advance directives, support services and what to expect next.
How to prepare
Bring the person who helps most with day-to-day care.
Good to know
Planning early keeps the person with the diagnosis at the center of decisions.
Q.

What treatment options exist today?

An overview, not a recommendation. The right mix depends on the diagnosis, its stage and your goals.

Overview of treatment approaches for memory disorders
ApproachWhat it aims to doWho it may suitMain considerations
Treating contributorsRemove or reduce things that worsen thinkingEveryone being evaluatedMedicine review, sleep, mood, hearing, vitamin B12, thyroid
Risk-factor controlProtect blood vessels and brain over timeEveryone, at any stageBlood pressure, blood sugar, cholesterol, activity, smoking
Symptomatic medicinesEase memory and function symptoms for a timePeople with Alzheimer's dementia and some other dementiasBenefits vary; side effects such as nausea or dizziness
Anti-amyloid antibodiesClear amyloid and modestly slow early declineSelected people with MCI or mild dementia due to Alzheimer'sARIA risk, MRI monitoring, frequent visits, cost; benefit size debated
Support and planningKeep life safe, meaningful and well organizedPeople with a diagnosis and their familiesDriving, finances, legal planning, caregiver support
Research participationAccess to studies and help find better treatmentsPeople at many stages, including healthy volunteersVoluntary; placebo possible; you can leave at any time

Read the full article on lecanemab and donanemab

Sources

  1. Dickerson BC, Atri A, Clevenger C, et al. The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for specialty care. Alzheimers Dement. 2025;21(1):e14337. View source (opens in a new tab)
  2. Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535. View source (opens in a new tab)
  3. U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer's disease (Kisunla, donanemab-azbt). July 2, 2024. View source (opens in a new tab)
  4. Alzheimer's Association. Alzheimer's Association welcomes FDA approval of Leqembi subcutaneous starter dose. July 13, 2026. View source (opens in a new tab)
  5. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377. View source (opens in a new tab)
  6. Rabinovici GD, Selkoe DJ, Schindler SE, et al. Donanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2025;12(5):100150. View source (opens in a new tab)
  7. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. View source (opens in a new tab)

Worried about memory changes in you or someone you love?

Email [email protected] and the office will reply with how to book a visit with Dr. Aggarwal at Rush University Medical Center.